Citi raised the firm’s price target on Argenx (ARGX) to $796 from $681 and keeps a Buy rating on the shares. With the backdrop of multiple macro uncertainties driving a risk-off environment and pressuring small-cap biotech valuations, stocks with strong fundamentals, near-term catalysts, and/or takeover potential will be prioritized by investors, the analyst tells investors in a research note. Citi views Argenx as a preferred name in the space. The company continues to grow Vyvgart revenue with multiple opportunities for further expansion on the horizon, contends Citi.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx Se’s Growth Potential Bolstered by Vyvgart Hytrulo Approval and Strategic Positioning
- Vyvgart for self-administration ‘immaterial’ to Option Care, says JPMorgan
- Argenx Se: FDA Approval and Strategic Developments Drive Buy Rating
- Argenx SE Gains FDA Approval for VYVGART Hytrulo Self-Injection Option
- Closing Bell Movers: Futures turn higher, gold hits new record